

Figure e-3. Control antigen-specific antibodies in CSF and serum before (V0) and after 12 months of natalizumab treatment (V12). Serum and CSF levels of antibodies reactive to **(A)** mumps virus, **(B)** influenza A virus, **(C)** influenza B virus, **(D)** enterovirus, **(E)** tetanus toxoid, **(F)** diphtheria toxoid, **(G)** *H. pylori* and **(H)** *C. pneumoniae* (*C. pneu.*) are depicted in arbitrary units (AU). Intrathecal production of the respective antibodies is indicated by CSF/serum antigen-specific antibody index (CAI_{Mumps}, CAI_{Influenza A}, CAI_{Influenza B}, CAI_{Enterovirus}, CAI_{Tetanus}, CAI_{Diphtheria}, CAI_{*H. pylori*}, CAI_{*C. pneu.*}). The p-value is shown in case of statistically significant differences. Statistics: Wilcoxon-matched pairs test (A-H).

